Curated News
By: NewsRamp Editorial Staff
April 14, 2025
Soligenix Reports Positive Results in Ongoing CTCL Study
TLDR
- Soligenix announced positive interim results for extended HyBryte treatment in CTCL patients, showing a strong response advantage over other therapies.
- Soligenix is developing HyBryte as a novel photodynamic therapy for CTCL, with promising results in ongoing IIS studies.
- Soligenix's innovative therapy offers hope to CTCL patients with limited treatment options, aiming to improve outcomes and quality of life.
- Soligenix's study on extended HyBryte treatment in CTCL patients presents exciting advancements in rare disease treatment research.
Impact - Why it Matters
This news matters as it highlights a potential breakthrough in treating CTCL, an orphan disease with limited therapeutic options. The positive interim results and ongoing development efforts by Soligenix offer hope to patients and underscore the importance of addressing unmet medical needs.
Summary
Soligenix (NASDAQ: SNGX) announced interim results from an ongoing study evaluating extended HyBryte(TM) treatment for patients with early-stage CTCL, showing strong treatment responses. The CEO highlighted the therapy's effectiveness in addressing an unmet medical need.
The company's Specialized BioTherapeutics business segment focuses on developing HyBryte(TM) as a novel photodynamic therapy for CTCL. Soligenix is working on advancing enrollment in a Phase 3 study to support potential commercialization worldwide.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Soligenix Reports Positive Results in Ongoing CTCL Study
